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Abstract. The purpose of this study was to determine 
the patterns of iodine- 131 613-iodomethylnorcholesterol 
(NP-59) imaging and the correlation with computed to- 
mography (CT)-guided adrenal biopsy and follow-up in 
patients with bilateral adrenal masses. To this end we in- 
vestigated a consecutive sample of 29 euadrenal patients 
with bilateral adrenal masses discovered on CT for rea- 
sons other than suspected adrenal disease. Adrenal scin- 
tigraphy was performed using 1 mCi of NP-59 injected 
intravenously, with gamma camera imaging 5-7 days la- 
ter. In 13 of the 29 patients bilateral adrenal masses were 
the result of metastatic involvement from lung carcino- 
ma (5), lymphoma (3), adrenocarcinoma of the colon 
(3), squamous cell carcinoma of the larynx (1), and ana- 
plastic carcinoma of unknown primary (1). Among these 
cases the NP-59 scan demonstrated either bilaterally ab- 
sent tracer accumulation (in eight, all with bilateral me- 
tastases proven by CT-guided biopsy or progression on 
follow-up CT) or marked asymmetry of adrenocortical 
NP-59 uptake (in five). Biopsy of the adrenal demon- 
strating the least NP-59 uptake documented malignant 
involvement of that gland in five of five patients. In two 
patients an adenoma was found simultaneously in one 
adrenal with a contralateral malignant adrenal mass. In 
each of these cases, the adenoma demonstrated the 
greatest NP-59 uptake. In 16 patients diagnosis of ade- 
noma was made on the basis of (a) CT-guided adrenal 
biopsy of the gland with the greatest NP-59 uptake of 
the pair (n=4), or (b) adrenalectomy (n=2), or (c) ab- 
sence of change in the size of the adrenal mass on fol- 
low-up CT scanning performed 6 months to 3 years later 
(n=10). It is concluded that differential in vivo function- 
al information provided by NP-59 scintigraphy comple- 
ments that derived from anatomic imaging and can be 
used in patients with bilateral adrenal masses to select 
which gland would be the best choice for further diag- 
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nostic invasive evaluation (e.g., adrenal biopsy) or may 
suggest the presence of bilateral adrenal metastases in 
patients with incidentally discovered, bilateral adrenal 
masses. 
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Introduction 
The unexpected finding of a unilateral adrenal mass on 
computed tomography (CT) in a patient studied for rea- 
sons other than suspected adrenal dysfunction is not an 
uncommon occurrence in our sophisticated high-resolu- 
tion, anatomical imaging environment [1-3]. The major- 
ity of these incidentally discovered masses or "inciden- 
talomas" are benign, even in patients with known nonad- 
renal malignancies, despite the relatively high predilec- 
tion for the adrenal as a site of metastasis of some tu- 
mors (e.g., lung and breast) [3-6]. Once their hormonal 
secretory status has been elucidated, further diagnostic 
attention must be paid to these masses to distinguish ad- 
renal adenoma fi'om metastasis [6-8]. 
In contrast, incidentally discovered bilateral adrenal 
masses are much less common. The diagnostic problems 
posed by bilateral adrenal masses have not been evaluat- 
ed in large series, but have been noted anecdotally. In 
this report, we examine a subset of patients (29 of a total 
of 258) with incidentally discovered adrenal masses 
studied in our laboratory over a 16-year period. In previ- 
ous reports we have documented the useful role of adre- 
nocortical scintigraphy in depicting function of the uni- 
lateral, incidentally discovered, adrenal mass [4, 6, 
9-11]. This report expands the use of iodine-131 613- 
iodomethylnorcholesterol (NP-59) to the evaluation of 
patients with incidentally discovered, bilateral adrenal 
masses. 
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Table  1. NP-59 scintigraphy in bilater- 
al nonhypersecretory adrenal masses Imaging pattern Lesion diameter (+_SD) Diagnosis 
Left Right 
(range) (range) 
Bilateral 2.6+1.5 cm 2.2+1.5 cm 
symmetric (2-5 cm) (2-5 cm) 
visualization (8) 
Bilateral 2.4+_ 1.4 cm 2.9_+ 1.4 cm 
asymmetric (1-5 cm) (1-5 cm) 
visualization (13) 
Bilateral 4.4+1.6 cm 5.6-+1.7 cm 
nonvisualization (8) (2-7 cm) (3.5-10 cm) 
Adenoma (8)" 
Adenoma (8) b 
Carcinoma° 
Colon (2) '1 







a Proven by no change in CT contour>6 months in seven cases, and by CT-guided bilateral 
biopsy in one 
b Proven by CT-guided adrenal biopsy in five cases (mass with increased NP-59 uptake) 
and by no change in CT contour in>6 months in three 
c Proven by CT-guided adrenal biopsy (mass with decreased NP-59 uptake) in three cases 
and by bilateral biopsy in two 
d One patient with an adrenal adenoma and a coexistent contralateral adrenal metastasis 
e Proven by CT-guided adrenal biopsy of largest mass in three cases and by bilateral biop- 
sy in four, and all with CT evidence of progression 
Materials and methods 
Between January 1976 and January 1992, 258 patients with adre- 
nal masses discovered incidentally during CT examinations of the 
abdomen or chest performed for reasons other than clinically sus- 
pected adrenal disease were studied with NP-59 scintigraphy. 
Twenty-nine of the 258 patients had bilateral adrenal masses. CT 
was initially performed on an EMI-5005, and later on a Picker 
1200SX at the VA Medical Center, Ann Arbor, and GE-8800 or 
GE-9800 scanners at the University of Michigan Medical Center. 
Contiguous 5- to 10-mm sections on the newer scanners were ob- 
tained after intravenous (IV) and/or oral radiographic contrast ad- 
ministration. Adrenal biopsies were performed either at or within 
1 week of the time of the initial CT and were done before NP-59 
scintigraphy. 
All patients referred for NP-59 scintigraphy gave their written 
informed consent for the study, which was approved by each hos- 
pital's Institutional Review Board for Human Experimentation. 
One mCi of NP-59 was injected IV and was followed by posterior, 
anterior, and lateral abdominal scans (50000 counts per image) 
performed on days 5 and/or 7 after injection [12]. Saturated potas- 
sium iodide solution, 1 drop, was administered thrice daily, 24 h 
prior to and throughout the imaging sequence to suppress thyroi- 
dal uptake of free 1311. A mild laxative (bisacodyl) was also given, 
10 mg, twice daily, to most patients beginning 2 days before the 
1 st day of planned imaging to reduce potentially interfering colon- 
ic 131I radioactivity [13]. 
In each patient various combinations of blood and urine bio- 
chemical measurements were obtained the exclude the presence of 
adrenal cortical or medullary dysfunction. These included in most 
cases, normal plasma levels of cortisol, renin activity, aldosterone, 
epinephrine, norephinephrine, urinary 17-hydroxycorticosteroids, 
17-ketosteroids, and vanillymandelic acid, and normal cortisol re- 
sponses to dexamethasone and in some cases adrenocorticotro- 
phin (ACTH) administration. All medications that might interfere 
with either the scintigraphic or the biochemical studies were 
stopped prior to study. One of these 29 cases has been included in 
a study of scintigraphy in adrenal masses [9], and magnetic reso- 
nance imaging (MRI) of 10 of the 29 has been previously report- 
ed [14, 15]. 
The relationship of relative NP-59 uptake between the adrenals 
was assessed qualitatively. Under these circumstances evaluation 
was more difficult than with unilateral lesions as there was no 
morphologically normal adrenal in which the level of NP-59 up- 
take might be considered "normal" [10, 11]. Thus, in patients with 
CT-demonstrated bilateral adrenal masses, the presence of identi- 
fiable adrenal NP-59 uptake that visually approximated or exceed- 
ed that of the contralateral adrenal and/or liver (a tissue that accu- 
mulates NP-59) was considered compatible with a benign process 
(e.g., an adenoma), while markedly decreased or absent NP-59 
uptake as compared to the contralateral adrenal and/or liver was 
considered abnormal and compatible with a destructive space-oc- 
cupying or malignant adrenal mass. Bilaterally symmetric NP-59 
uptake (within the limits of the normal and previously established 
degree of adrenal asymmetry) was considered normal [16]. Statis- 
tical analyses were performed using Student's t test [17]. 
Results 
All 29 patients had bilateral adrenal masses on CT. The 
clinical indications for CT were a search for metastases 
in 17, abdominal pain in nine, and ascites, renal failure, 
and pneumonia in one case each. The mean lesion diam- 
eter was 3.3+_1.4 cm (range: 1-7 cm) on the right, and 
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Fig. 1. CT scans (left and center panels) depict bilateral adrenal metastases (arrows) from lung carcinoma. Posterior NP-59 scan (right 
panel) shows bilateral non-visualization of the adrenals 
Fig. 2. CT scan (left panel) depicts 
bilateral adrenal masses (arrows) 
in a patient with metastatic 
adrenocarcinoma of the colon. 
Posterior NP-59 scan of the abdo- 
men (right panel) demonstrates 
asymmetric tracer (right>left) up- 
take. CT-guided adrenal biopsy of 
the right adrenal was benign, 
while that of the left adrenal dis- 
closed adenocarcinoma 
Fig. 3. CT scans (left and center panels) identify bilateral adrenal masses (arrows). Posterior abdominal NP-59 scan depicts symmetric 
adrenal uptake (arrows). Bilateral CT-guided adrenal biopsy was negative for malignancy 
3.4_+1.5 cm (range: 1-10 cm) on the left (P=ns) (Table 1). 
CT-guided adrenal biopsies were performed in 19 of the 
29 patients. Unilateral adrenal biopsy was performed in 
12 of 19 patients while bilateral adrenal biopsies were 
done in the remaining seven. Adrenal biopsy was per- 
formed as part of  a research protocol during the interval 
from 1985 to 1988 [14, 15] while biopsies performed be- 
fore 1985 and after 1988 were done as deemed neces- 
sary for clinical diagnostic purposes. All biopsies were 
done at the time of initial CT or shortly thereafter. Bilat- 
eral adrenal biopsies were performed when considered 
feasible, based upon the clinical status of  the patient, ac- 
cessibility of  both masses for biopsy, and the degree of 
clinical suspicion of metastasis to the adrenals. When 
unilateral biopsies were performed, the larger of the two 
masses was usually selected for biopsy. Metastases were 
eventually determined to be present in 13 patients: lung 
carcinoma in five, lymphoma in three, adenocarcinoma 
of the colon in three, laryngeal carcinoma in one, and 
anaplastic carcinoma of unknown origin in one. In 16 
cases an eventual diagnosis of adenoma was made by 
adrenal biopsy in four, by unilateral adrenalectomy in 
two, and by unchanged findings on repeat CT scans per- 
formed at 6 months to 3 years after the initial CT exami- 
nation in the remaining 12 (including the two cases in 
which unilateral adrenalectomy was performed). 
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Variable patterns of NP-59 uptake were observed in 
the 29 patients with bilateral adrenal masses (Table 1). 
Bilateral nonvisualization was observed in eight patients 
in whom CT-guided adrenal biopsy confirmed metastatic 
involvement in one or both glands, and with progression 
on follow-up CT (Fig. 1). CT-guided adrenal biopsy per- 
formed in five of eight patients with asymmetric NP-59 
uptake demonstrated that those adrenals with the great- 
est NP-59 accumulation of the pair (adrenal cortical up- 
take exceeding the contralateral adrenal or equal to liver) 
had benign cytology compatible with adenoma. The re- 
maining three cases showed no change in adrenal con- 
tour over at least a 6-month follow-up period. Alterna- 
tively, CT-guided adrenal biopsy of masses exhibiting 
marked asymmetry of NP-59 uptake were the biopsy 
was directed to the gland exhibiting the least NP-59 up- 
take of the pair (less than the contralateral adrenal and/or 
liver) revealed metastatic disease on cytology in five of 
five patients (Table 1). 
In two patients with markedly asymmetric NP-59 up- 
take, an adenoma in one adrenal was found to coexist 
with a contralateral metastatic deposit (lung and colon 
carcinoma, respectively) (Fig. 2), while of the remaining 
eight patients, all with bilaterally symmetric NP-59 up- 
take, seven had no change in adrenal contour over at 
least a 6-month follow-up period (Table 1). The remain- 
ing patient with bilateral 2-cm-diameter adrenal masses, 
had CT-guided biopsy evidence of adenoma (Fig. 3). 
Discussion 
Although a far less common problem, the clinical dilem- 
ma posed by incidentally discovered bilateral adrenal 
masses is not unlike that of the unilateral adrenal mass. 
Diagnosis is first dependent upon a hormonal evaluation 
sufficient to exclude either a hypersecretory state from 
bilateral adrenal sources or adrenal insufficiency due to 
complete destruction of the adrenal cortex [1, 2, 18]. Ad- 
renal gland dysfunction with bilateral masses has been 
observed in primary aldosteronism [19], hypercortiso- 
lism due to either bilateral adenoma [20] or bilateral cor- 
tical nodular hyperplasia [21], congenital adrenal hyper- 
plasia [22], pheochromocytoma particularly in the multi- 
ple endocrine neoplasia syndromes 2A and 2B [23, 24], 
and neuroblastoma [25]. Adrenocortical hypofunction 
with bilateral masses has been reported in tuberculosis 
[26], fungal diseases [27], bilateral adrenal hemorrhage 
[28], and rarely adrenal destruction from bilateral, pri- 
mary adrenal neoplasms [29, 30] or as a result of bilater- 
al metastases to the adrenals [31, 32]. The commonest 
sources of metastases to the adrenal are from tung carci- 
noma (bronchogenic) followed by breast, thyroid, and 
renal carcinoma, melanoma, and non-Hodgkin's lym- 
phoma [31, 32]. In patients with underlying malignancy, 
adrenal metastases are usually noted in the presence of 
extensive metastatic disease to other sites (e.g., liver, 
bone, and lymph nodes). In this setting adrenal masses 
do not constitute a major diagnostic or therapeutic prob- 
lem. However, when a patient has a known primary ma- 
lignancy and adrenal masses and no other evidence of 
metastases, the presence of adrenal masses raises critical 
issues of tumor staging and further management. 
Both CT and MRI have been used to identify bilateral 
adrenal masses and distinguish benign from malignant 
neoplastic involvement [2, 3, 15, 33-35]. Characteristic 
patterns of imaging seen on CT have demonstrated high 
sensitivity and specificity [33, 36, 37]. Recently devel- 
oped MRI pulse sequences have been used to distinguish 
benign from malignant masses in some patients [38, 39]. 
However, up to one-third of adrenal masses may not be 
correctly characterized by CT or MRI [2, 14, 15, 40]. 
Many series of incidentally discovered adrenal lesions 
report a small number of patients who present on CT (or 
MRI) with incidentally discovered bilateral adrenal 
masses. These series have generally considered each of 
the neoplasms as separate lesions and interpretative at- 
tention has been placed upon an analysis of "individual" 
masses according to diagnostic criteria versus normal. 
There has not been a detailed comparison of one side 
versus the other with respect to anatomic and functional 
characteristics. Scintigraphic evaluations use the accu- 
mulation of radiocholesterol as an in vivo marker of dif- 
ferential adrenal cortical function. Thus, a reduction in 
or absence of adrenal 131I-NP-59 uptake in non-dexa- 
methasone-suppressed patients suggests adrenal gland 
replacement or destruction due to involvement with neo- 
plasm or other space-occupying lesions [2, 4, 10, 11]. 
A nonexhaustive, but representative review of the lit- 
erature published between 1981 and 1994 notes 632 
cases of adrenal masses of which 108 (17%) were bilat- 
eral [5-8, 14, 33, 35, 37, 39-49] (Table 2). Of those pa- 
tients with bilateral adrenal masses in whom data were 
available that distinguished benign from malignant 
masses, 52% had malignant involvement of the adrenals. 
In the present series, 29 of 258 (11%) had incidentally 
discovered bilateral adrenal masses, and 13 of the 29 
(45%) had metastatic disease to one (2 of 13) or both (11 
of 13) adrenals. Bilateral benign masses were noted in 
16 of the 29 patients (55%) despite the fact that 17 
(59%) had a preexisting malignancy. Thus, in our series 
it is slightly more likely that a patient presenting with bi- 
lateral adrenal masses would have bilateral benign rather 
than malignant adrenal involvement, even in the pres- 
ence of a preexisting malignancy elsewhere. Our data 
may differ from the published literature as a result of re- 
ferral bias, as we considered only those cases of truly in- 
cidental and nonhypersecretory adrenal masses. 
More intriguing is the simultaneous presence of a be- 
nign non-hypersecreting adenoma and a contralateral ad- 
renal metastasis, a phenomenon that has been previously 
reported [41, 45] and was documented in two cases in 
our series. Furthermore, multiple metastases to one 
gland [45] and an unusual case of a metastasis to an ad- 
renal adenoma have also been noted [50]. There are also 
reports of bilateral adrenal masses in which one adrenal 
lesion was hypersecreting (e.g., aldosteronoma) while the 
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Authors Year Total Bilateral Benign Malignant 
cases 
Cedarmark and Ohlsen 1981 5 a 2 0 2 d 
Zornoza et al. 1981 21 a 2 b _ _ 
Heaston et al. 1982 14 c 2 1 1 
Berkman et al. 1984 16 2 b - - 
Oliver et al. 1984 32 6 4 2 
Hussain et al. 1985 43 a 5 2 3 
Abecasis et al. 1985 21 2 2 0 
Katz and Shirkhoda 1985 16 c 7 3 4 
Belldegrun et al. 1986 38 a 6 3 3 d 
Hussain et al. 1986 57 6 0 6 
Glazer et al. 1986 28 a 5 2 3 
Doppman et al. 1987 81 a 13 b - - 
Berland et al. 1988 44 ° 7 b,f - - 
Reincke et al. 1989 32 a 8 b - - 
Krestin et al. 1989 25 ~ 4 2 2 
Virkkala et al. 1989 20 2 2g 0 
Khafagi et al. 1991 45 h 6 0 6 
Jockenhovel et al. 1992 36 a 4 b - - 
Reinig et al. 1994 53 a 7 b - - 
Haab et al. 1994 12 a 12 10 2 
Total 632 108 (17%) 31 (48%) 34 (52%) 
a Series with hypersecreting and nonhypersecreting adrenal masses 
b Did not distinguish bilateral benign from bilateral malignant masses 
c Patients with known preexisting malignancy 
d Patient with coexisting ipsilateral benign and contralateral adrenal metastasis 
e Masses all <5 cm in diameter 
f Either bilateral benign or bilateral malignant masses 
g Patient with nonsuppressible urinary cortisol metabolites 
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Fig. 4. Diameter of adrenal bilateral masses. Each connected pair 
denotes the adrenal masses in a single patient. R, Right adrenal; L, 
left adrenal; I ,  adenoma; O, metastasis; *, nonvisualization on 
NP-59 scintigraphy 
other was a nonhypersecret ing adenoma [51, 52]. Per- 
haps, a slowly expanding intra-adrenal metastasis, a less 
aggressive primary malignancy,  or a nonglucocort icoid 
hypersecreting neoplasm would allow the development  of 
compensatory hyperplasia leading to a functioning,  but 
not hypersecretory, contralateral adrenal mass [53]. 
Recommenda t ions  for further diagnostic evaluations 
based upon the size of an adrenal  mass alone may be 
misleading.  Thus, in a patient  with bilateral  masses and 
a preexist ing cancer, b iopsy of the larger of the two 
masses may not  invariably disclose the presence of ma- 
l ignancy. In the current  series, 2 of 29 patients (2 of 13 
with asymmetr ic  NP-59 uptake) had an adenoma and a 
contralateral metastasis where the mal ignan t  mass was 
smaller  (2 and 3 cm versus 3 and 4 cm, respectively) 
than the benign  adenoma.  As a group the sizes of the 
mal ignant  masses were not s ignif icantly greater than the 
sizes of those that were ben ign  (Fig. 4). Further, in two 
reports of patients with pr imay aldosteronism and bilat- 
eral adrenal masses the smaller of the t w o  masses was 
later proven to be an aldosterone-secret ing adenoma 
while the larger mass was a nonhypersecretory adenoma 
[5 l, 521. 
The scintigraphic evaluat ion of bilateral  incidental ly  
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discovered adrenal masses represents a far more difficult 
problem than for unilateral lesions as the present inter- 
pretative algorithm depends upon the presence of an an- 
atomically normal contralateral adrenal gland (by CT 
criteria) for comparison [10]. Accumulation of NP-59 
that approaches or exceeds that of liver, a tissue that ac- 
cumulates NP-59, and bilateral but asymmetric NP-59 
uptake (that exceeds normal adrenal asymmetry) may be 
useful in guiding further invasive evaluation. In six cases 
(including the adenomas in the two patients with coexis- 
tent contralateral malignant masses) biopsy and in two 
cases adrenalectomy of the most prominent adrenal (that 
gland with the most NP-59 uptake as assessed visually) 
were benign, while biopsy of the adrenal mass with the 
least NP-59 uptake of the pair disclosed adrenal metas- 
tases in five cases. While these numbers are small, the 
results of NP-59 imaging in bilateral adrenal masses 
suggests that further studies (e.g., adrenal biopsy) would 
be best directed toward the adrenal mass with the least 
iodocholesterol uptake, since in a patient with a known 
malignancy it usually matters little to further diagnostic 
evaluation and therapy whether one or both glands are 
affected. Bilateral masses on CT with bilateral nonvisu- 
alization of the adrenals on NP-59 scintigraphy was pre- 
dictive of bilateral metastases in eight of eight patients. 
It was perhaps not surprising that this group had the 
largest adrenal masses (Table 1). The scintiscan depicts 
adrenal cortical effacement by neoplasm, a pattern of 
imaging that has been previously described [2, 6, 10, 11, 
54]. In some cases, exogenous hormone therapy to pro- 
tect against the development of adrenocortical insuffi- 
ciency may be contemplated if both adrenals are re- 
placed by a metastatic or other infiltrative processes 
[28-31]. It is, however, unusual for patients to present 
with adrenal cortical insufficiency from bilateral adrenal 
metastases since more than 90% of the adrenal must be 
replaced before cortical hypofunction becomes clinically 
apparent [30, 31]. 
Scintigraphy of bilateral adrenal masses may provide 
unique, non-invasive information regarding relative dif- 
ferential adrenal function that can be used to identify le- 
sions requiring further diagnostic evaluation [5]. The da- 
ta available to date document that adrenal masses, and 
especially bilateral adrenal masses, are of heterogeneous 
etiology. With respect to our series of incidentally dis- 
covered bilateral adrenal masses, the following conclu- 
sions seem most appropriate: 
1. Bilateral masses in patients with malignancies appear 
to be slightly more likely to be adenomas than metastases. 
2. Although the larger the mass the greater the likelihood 
of malignancy, size remains a poor discriminator of ma- 
lignancy in patients with bilateral adrenal masses in the 
2-5 cm range. 
3. Although the situation is uncommon, an adrenal ade- 
noma and a contralateral adrenal malignancy can coexist. 
4. NP-59 may be used to functionally characterize bilat- 
eral (and unilateral) adrenal neoplasms and as a means 
to select masses for further diagnostic evaluation(s). 
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